Adial Pharmaceuticals Inc

0.5726-0.0153-2.60%Vol 171.25K1Y Perf -80.00%
Aug 11th, 2022 15:59 DELAYED
BID0.5710 ASK0.5990
Open0.5880 Previous Close0.5879
Pre-Market- After-Market0.57
 - -  0.00 -0.28%
Target Price
8.67 
Analyst Rating
Strong Buy 1.00
Potential %
1.41K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/43 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-77 
Income Ranking
 —    -
Price Range Ratio 52W %
2.65 
Earnings Rating
Strong Buy
Market Cap14.69M 
Earnings Date
11th Aug 2022
Alpha0.00 Standard Deviation0.28
Beta0.74 

Today's Price Range

0.57000.6100

52W Range

0.45005.08

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-5.35%
1 Month
-61.83%
3 Months
-55.61%
6 Months
-73.61%
1 Year
-80.00%
3 Years
-65.92%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ADIL0.5726-0.0153-2.60
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.17-0.1323.53
Q03 2021-0.22-0.220.00
Q02 2020--0.16-
Q01 2020--0.22-
Q03 2019--0.17-
Q02 2019--0.21-
Q01 2019--0.33-
Q03 2018-0.31-0.85-174.19
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.165.88Positive
9/2022 QR-0.18-5.88Negative
12/2022 FY-0.616.15Positive
12/2023 FY-0.4021.57Positive
Next Report Date-
Estimated EPS Next Report-0.16
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume171.25K
Shares Outstanding25.65K
Shares Float23.25M
Trades Count489
Dollar Volume100.26K
Avg. Volume896.20K
Avg. Weekly Volume474.79K
Avg. Monthly Volume1.50M
Avg. Quarterly Volume714.86K

Adial Pharmaceuticals Inc (NASDAQ: ADIL) stock closed at 0.5726 per share at the end of the most recent trading day (a -2.6% change compared to the prior day closing price) with a volume of 171.25K shares and market capitalization of 14.69M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 4 people. Adial Pharmaceuticals Inc CEO is William B. Stilley.

The one-year performance of Adial Pharmaceuticals Inc stock is -80%, while year-to-date (YTD) performance is -78.79%. ADIL stock has a five-year performance of %. Its 52-week range is between 0.45 and 5.08, which gives ADIL stock a 52-week price range ratio of 2.65%

Adial Pharmaceuticals Inc currently has a PE ratio of -1.90, a price-to-book (PB) ratio of 3.91, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -154.92%, a ROC of -207.41% and a ROE of -214.36%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Adial Pharmaceuticals Inc, there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.16 for the next earnings report. Adial Pharmaceuticals Inc’s next earnings report date is -.

The consensus rating of Wall Street analysts for Adial Pharmaceuticals Inc is Strong Buy (1), with a target price of $8.67, which is +1 414.15% compared to the current price. The earnings rating for Adial Pharmaceuticals Inc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adial Pharmaceuticals Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adial Pharmaceuticals Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 23.91, ATR14 : 0.15, CCI20 : -53.11, Chaikin Money Flow : -0.37, MACD : -0.20, Money Flow Index : 25.32, ROC : -14.92, RSI : 25.42, STOCH (14,3) : 37.27, STOCH RSI : 0.88, UO : 44.97, Williams %R : -62.73), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adial Pharmaceuticals Inc in the last 12-months were: Bankole A. Johnson (Sold 400 000 shares of value $0 ), James W. Newman (Buy at a value of $28 500), William B. Stilley (Buy at a value of $110 141)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc is a United States-based pharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is an approved drug for treating nausea and emesis.

CEO: William B. Stilley

Telephone: +1 434 422-9800

Address: 1001 Research Park Boulevard, Charlottesville 22911, VA, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

64%36%

Bearish Bullish

55%45%

TipRanks News for ADIL

Tue, 28 Jun 2022 17:55 GMT Adial Pharmaceuticals (ADIL) Receives a Buy from Maxim Group

- TipRanks. All rights reserved.

News

Stocktwits